Loading...
XASE
AIM
Market cap12mUSD
Jul 22, Last price  
0.25USD
1D
1.77%
1Q
-51.27%
Name

AIM ImmunoTech Inc

Chart & performance

D1W1MN
XASE:AIM chart
P/E
—
P/S
139.39
EPS
—
Div yield, %
—
Shrs. gr., 5y
72.73%
Rev. gr., 5y
-11.60%
Revenues
88k
-48.24%
933,0001,059,000265,000111,000135,000161,000213,000150,000197,000133,00092,000437,000367,000140,000163,000135,000141,000202,000170,00088,000
Net income
-14m
L-19.41%
-19,399,000-18,139,000-12,219,000-13,438,000-13,136,000-9,015,000-17,354,000-16,225,000-17,450,000-15,230,000-7,502,000-8,259,000-9,813,000-9,404,000-14,400,000-19,127,000-19,445,000-28,962,000-17,320,000-13,958,000
CFO
-11m
L-26.40%
-13,747,000-15,112,000-9,358,000-9,297,000-11,886,000-10,096,000-13,136,000-16,830,000-13,918,000-16,053,000-7,380,000-7,941,000-10,640,000-9,067,000-10,368,000-13,965,000-16,108,000-21,267,000-14,888,000-10,957,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
URL
https://aimimmuno.com/
IPO date
Jul 12, 1996
Employees
22
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT